This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions

This study has been completed.
Information provided by (Responsible Party):
Novartis Identifier:
First received: January 9, 2002
Last updated: January 30, 2012
Last verified: January 2012
Patients with bone metastases or bone lesions caused by breast cancer, multiple myeloma or prostate cancer will be treated with IV Zometa in a 15 minute infusion. Pain will be evaluated, as well as time in chair, quality of life and safety of Zometa.

Condition Intervention Phase
Breast Cancer Multiple Myeloma Prostate Cancer Drug: zoledronic acid Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Prospective, Multicenter, Open-label Clinical Evaluation of the Effect of IV Zoledronic Acid 4mg on PAIN, QUALITY OF LIFE and TIME IN INFUSION CHAIR in Breast Cancer, Multiple Myeloma, and Prostate Cancer Patients With Cancer-related Bone Lesions

Resource links provided by NLM:

Further study details as provided by Novartis:

Primary Outcome Measures:
  • Pain score assessed by change from baseline

Secondary Outcome Measures:
  • Quality of life
  • Time in infusion chair
  • Safety assessed by adverse events (AEs)

Estimated Enrollment: 500
Study Start Date: October 2001
Study Completion Date: November 2002
Primary Completion Date: November 2002 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria

  • Signed informed consent
  • Greater than 18 years of age
  • Proof of breast cancer, multiple myeloma or prostate cancer
  • Diagnosis of at least one cancer-related bone lesion
  • If patient is of child-bearing potential, negative pregnancy test and on a medically recognized form of contraception
  • ECOG performance status of 0,1 or 2
  • Ability to read, understand and write English or Spanish language
  • Normal renal function
  • Corrected serum calcium equal to or greater than 8mg/dl Exclusion Criteria
  • clinically symptomatic brain metastases
  • hypersensitivity to Zometa or other bisphosphonates
  • pregnant or lactating
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00029224

United States, California
Stockton Hematology Oncology Medical Group
Stockton, California, United States, 95204
United States, Florida
Osceola Cancer Center
Kissimmee, Florida, United States, 34741
United States, Nevada
Nevada Cancer Center
Las Vegas, Nevada, United States, 89109
United States, New Mexico
Hematology-Oncology Associates PC
Albuquerque, New Mexico, United States, 87102
New Mexico Oncology Hematology Consultants
Albuquerque, New Mexico, United States, 87102
United States, Oregon
Hematology Oncology Associates, PC
Medforo, Oregon, United States, 97504
United States, Virginia
Virginia Physicians, Inc
Richmond, Virginia, United States, 23294
Sponsors and Collaborators
  More Information

Responsible Party: Novartis Identifier: NCT00029224     History of Changes
Other Study ID Numbers: CZOL446EUS16
Study First Received: January 9, 2002
Last Updated: January 30, 2012

Keywords provided by Novartis:
bone lesions
breast cancer
multiple myeloma
prostate cancer
bone metastases

Additional relevant MeSH terms:
Breast Neoplasms
Prostatic Neoplasms
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Site
Breast Diseases
Skin Diseases
Genital Neoplasms, Male
Urogenital Neoplasms
Genital Diseases, Male
Prostatic Diseases
Neoplasms by Histologic Type
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Zoledronic acid
Bone Density Conservation Agents
Physiological Effects of Drugs processed this record on August 16, 2017